Announce a new program for the liver-targeted genetic disease franchise
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2026
- Due
- 30 Jun 2026
- Delivered
- 24 Feb 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Beam expects to disclose the next clinical program for its liver-targeted genetic disease franchise in the first half of 2026.”
What we found
Evidence strength A What the grades mean
Beam Therapeutics announced a new liver-targeted genetic disease program, BEAM-304 for phenylketonuria (PKU), in a filing dated February 24, 2026, which is within the first half of 2026.
-
A Beam Therapeutics Inc. 8-K filed 2026-02-24
“Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 8-K filed 2026-02-24
“In addition, the company announced the expansion of its liver-targeted genetic disease franchise with a new program, BEAM-304, for the treatment of phenylketonuria (PKU)” ✓ confirmed on the page
Market reaction: the shares moved +1.1% against the S&P 500 over the three sessions around the disclosure (23 Feb 2026 to 26 Feb 2026). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Announce
- Deliverable
- New liver-targeted genetic disease program
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-BEAM-003317 · Corrections policy